A strategy that analyzes the structural properties of RNA could help identify regions that are promising targets for antiviral drugs.

The SAIR database is designed to help scientists train AI models to better predict protein-ligand binding affinities for drug ...

On Thursday, 19 June, the National Institute for Health and Care Excellence (NICE) published final draft guidance for donanemab and lecanemab, the first disease-modifying treatments for early ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...